Curaleaf (OTCMKTS:CURLF) Raised to “Strong-Buy” at Zacks Research

Curaleaf (OTCMKTS:CURLF) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Curaleaf Price Performance

Shares of CURLF stock traded up $0.09 during trading on Tuesday, hitting $3.90. The company had a trading volume of 267,469 shares, compared to its average volume of 1,026,705. The stock’s 50-day moving average is $2.55 and its two-hundred day moving average is $2.59. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -30.00 and a beta of 1.58. The company has a quick ratio of 0.76, a current ratio of 1.52 and a debt-to-equity ratio of 1.14. Curaleaf has a 52 week low of $0.72 and a 52 week high of $5.05.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Tuesday, May 5th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.17. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.06%. The business had revenue of $324.23 million during the quarter, compared to analyst estimates of $316.62 million. As a group, analysts predict that Curaleaf will post -0.26 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.